osimertinib
astrazeneca
['lung', 'adaura', 'nsclc', 'sclc', 'osimertinib', 'aura ,(-laura)']
osimertinib improved os, 51 % reduction in the risk of death in egfr (+) patients with stage ii and iii nsclc not just dfs. now make sure you test every resected lung ca patient, no ifs ands or buts. #asco2023 #adaura #lungcancer #precisionmedicine #egfr 
Medical Oncologist and Hematologist at Kettering Cancer Center in Dayton, OH. Program Director Hematology and Oncology Fellowship.